Results 71 to 80 of about 2,108 (191)

Cytokine Engineering Approaches for Regenerative Medicine

Advanced Therapeutics, Volume 8, Issue 9, September 2025.
Engineered cytokines represent a powerful strategy to promote tissue repair and regeneration by precisely modulating immune responses. This review highlights recent advances in cytokine engineering, including strategies to enhance half‐life, improve tissue and cell targeting, and control receptor signaling.
Shiyi Li, Wenhao You, Mikaël M. Martino
wiley   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept [PDF]

Purpose Some patients with neovascular age-related macular degeneration (nAMD) do not respond to anti-VEGF treatment or develop tolerance or tachyphylaxis.
Bjerager, Jakob, Hajari, Javad Nouri, Hodzic-Hadzibegovic, Delila, Klefter, Oliver Niels, Schneider, Miklos, Subhi, Yousif   +5 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study [PDF]

Purpose: To present the rationale and design of the Tailored Anti-VEGF therapy with New Generation Optimizations (TANGO) treatment regimen for neovascular age-related macular degeneration and to simulate potential number of visits and injections with ...
Andersen, Lena, Hajari, Javad, Henningsen, Naayaab, Larsen, Karin, Schneider, Miklos, Subhi, Yousif   +5 more
core   +1 more source

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema

Ophthalmology and Therapy
Introduction This study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.
Viktoria Deiters, Anna Lorger, Franziska Eckardt, Jakob Siedlecki, Benedikt Schworm, Siegfried G. Priglinger, Tina R. Herold   +6 more
doaj   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Do ranibizumab intravitreal injections with laser therapy improve visual acuity in diabetic retinopathy patients better than monotherapy of intravitreal ranibizumab injections? [PDF]

, 2023
Objective: The objective of this selective EBM review is to determine whether or not combination therapy of intravitreal ranibizumab injections plus laser photocoagulation increases best corrected visual acuity (BCVA) in adults with diabetic ...
Sawtelle, Daniel P.
core   +1 more source

Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration [PDF]

Objectives This study entailed a weekly analysis of real-world data (RWD) on the safety and efficacy of intravitreal (IVT) faricimab in neovascular age-related macular degeneration (nAMD).
Blaser, Frank, Fasler, Katrin F, Kvanta, Anders, Muth, Daniel R, Rejdak, Magdalena, Zweifel, Sandrine A   +5 more
core   +1 more source

Anti-VEGFs for Diabetic Macular Oedema:Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective [PDF]

Introduction: Frequent intravitreal injections of anti-vascular endothelial growth factors (VEGFs) for diabetic macular oedema (DMO) pose challenges for healthcare systems, patients, and society.
Amarakoon, Sankha, Carrasco, Joao, Crossan, Catriona, Lunk, Izabella, Nikodem, Mateusz, Paulissen, Jeroen H.J., Pochopien, Michal, Postma, Maarten J., Quist, Sara W., van Asten, Freekje, Woudstra, Marrit A.   +10 more
core   +1 more source